Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Relief Therapeutics Holding AG
  6. Company
    RLF   CH0100191136

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  11:30 2022-12-05 am EST
0.0292 CHF   -0.68%
11/21APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
EQ
11/16Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
EQ
11/14Relief Therapeutics, NRx Pharmaceuticals Sign Deal to Resolve Aviptadil Dispute
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Relief Therapeutics Holding AG
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The CompanyÔÇÖs objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
Sales per Business
20202021Delta
Biopharmaceutical Products--3.32100%-
CHF in Million
Sales per region
2021
Europe (excluding Switzerland)1.1233.6%
Rest of the World0.8425.4%
North America0.8425.1%
Switzerland0.5315.9%
CHF in Million
Managers
Name Title Age Since
Jack M. Weinstein Chief Financial Officer & Treasurer 65 2020
Nermeen Varawalla, Dr. Chief Medical Officer - 2021
Paolo Galfetti Chief Operating Officer & Director - 2022
Raghuram Selvaraju, Dr. Chairman 43 2016
Christopher Wick Executive Director & Head-Sales US Region - -
Marco Marotta Chief Business Officer - 2021
Anthony M. Kim Senior VP & Head-US Commercial Operations - 2021
Drew Cronin-Fine Executive Director & Head-US Marketing - 2022
Jeremy Meinen Chief Accounting Officer - 2021
Members of the board
Name Title Age Since
Raghuram Selvaraju, Dr. Chairman 43 2016
Thomas Plitz, Dr. Director 53 2020
Paolo Galfetti Chief Operating Officer & Director - 2022
Patrice P. Jean Director - 2021
Michelle Lock Director - 2022
Drew Cronin-Fine Executive Director & Head-US Marketing - 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 4,616,334,617 3,027,638,346 65.6% 223,493,832 4.8% 65.6%
Shareholders
NameEquities%
Global Emerging Markets North America, Inc. 1,158,000,000 26.2%
Relief Therapeutics Holding AG 218,936,253 4.96%
BG Consulter GmbH 136,343,167 3.09%
Credit Suisse Asset Management (Schweiz) AG 29,870,396 0.68%
BlackRock Fund Advisors 26,591,890 0.60%
Paolo Galfetti 18,250,174 0.41%
UBS Asset Management Switzerland AG 14,083,659 0.32%
Pictet Asset Management SA 3,585,290 0.081%
BlackRock Asset Management Schweiz AG 2,760,386 0.063%
TIAA-CREF Investment Management LLC 2,475,027 0.056%
Holdings
NameEquities%Valuation
RELIEF THERAPEUTICS HOLDING AG (RLF) 218,936,253 4.96% 5,906,900 USD
Company contact information
RELIEF THERAPEUTICS Holding AG
Avenue de SÚcheron 15
BÔtiment F2/F3
Geneva, Geneve (Geneva) 1202

Phone : +41.44.723.59.59
Fax : +41.44.726.90.12
Web : http://www.relieftherapeutics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Relief Therapeutics Holding AG